LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
$१.६३
arrow_upward
+१.२४%(+०.०२०) 1D
$१.६४
arrow_upward
+०.४०% (+०.००६५)bedtimeAfter hours
Closed: १ मे, ४:००:०१ PM [GMT]-४ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | किंमत | बदल | % बदल |
|---|
insights_autoLXRX साठी टॉप इनसाइट जनरेट करत आहे...
उघडा
$१.५९
उच्च
$१.६६
कमी
$१.५८
मार्केट कॅप
६९.०६ कोटी
सरासरी उलाढाल
२३.१७ लाख
उलाढाल
१३.९८ लाख
५२ आठवड्यांतील उच्चांक
$१.९५
५२ आठवड्यांतील नीचांक
$०.५१
EPS
-$०.१४
बीटा
१.३६
थकित शेअर
४२.३७ कोटी
कर्मचाऱ्यांची संख्या
८१
बातम्यांच्या स्टोरी
संपूर्ण वेबवरील स्रोतांकडून
Yahoo Finance
·
२ दिवसांपूर्वी
Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851
प्रोफाइल
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Lexicon Pharmaceuticals Inc बद्दल
AI आशयामध्ये चुका असू शकतात. अधिक जाणून घ्या